Article

The Latest News and Updates in Metastatic Breast Cancer

Author(s):

A roundup of the latest news and updates for patients with metastatic breast cancer from CURE®.

There have been several updates in the field of metastatic breast cancer over the last several weeks.

Here, CURE® looks back at some of the latest news and updates affecting patients with metastatic breast cancer.

  • Metastatic breast cancer creates a high economic burden, especially among women aged 45 years to 64 years, through lost productivity, according to the results of a productivity cost analysis published in Cancer.
  • The combination of pyrotinib plus Xeloda (capecitabine) provides a better progression-free survival (PFS) rate than Tykerb (lapatinib) plus Xeloda in patients with HER2-positive metastatic breast cancer (mBC) who were previously treated with Herceptin (trastuzumab) and chemotherapy, according to recent data.
  • First-line treatment with Keytruda (pembrolizumab) in combination with chemotherapy improves progression-free survival in patients with locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC), according to data presented at the 2020 ASCO Virtual Scientific Program.
  • The phase 3 Impassion131 study — designed to evaluate the immunotherapy Tecentriq (atezolizumab) in combination with the chemotherapy paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer (TNBC) — failed to meet its primary endpoint of improving progression-free survival, compared with placebo plus paclitaxel.
  • Recently, updated findings of the phase 2 HER2CLIMB study demonstrated that patients with HER2-positive metastatic breast cancer who developed brain metastases experienced a 52% reduction in the risk of death after receiving the combination of Tukysa (tucatinib), Herceptin (trastuzumab) and capecitabine.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with grey hair.
a man and a woman in front of a dark blue background
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Image of woman with blonde hair.
Image of a woman with wavy blonde hair wearing glasses.
Image of a woman wearing a red tank top.
Image of Annie Bond.
Expert on TNBC, with patient
Addressing Unmet Needs Session Panel
Dr. Beverly Moy
Related Content